Comparison between the antimicrobial activity of colistin and ceftazidime-avibactam against multidrug-resistant Pseudomonas aeruginosa isolated from patients with ventilator-associated pneumonia in intensive care units of Kasr Al-Ainy hospitals
Abstract
BACKGROUND: With the growing challenge of antibiotic resistance, evaluating the effectiveness of existing antimicrobials is crucial. This work aimed to compare the antimicrobial activity of colistin versus ceftazidime/avibactam (CAZ/AVI) against MDR P. aeruginosa. It also aimed to estimate the prevalence of P. aeruginosa as a causative agent for VAP and the rate of its multi-drug resistance. METHODS: This observational cross-sectional study was conducted from January to June 2025 on ICU patients with VAP at Kasr Alainy Hospitals. A total of 120 endotracheal aspirates were collected from patients and cultured. P. aeruginosa was identified, tested for antibiotic susceptibility by the Kirby-Bauer disc diffusion method, and underwent colistin minimal inhibitory concentration (MIC) testing via broth microdilution and CAZ/AVI MIC determination using E-test, following the Clinical and Laboratory Standards Institute 2025 guidelines. RESULTS: Of 120 ICU patients diagnosed with VAP, P. aeruginosa was isolated from 47 (39.2%). Among these, 40 isolates (85.1%) were identified as MDR. Of 40 MDR P. aeruginosa isolates, 32 (80%) were susceptible to colistin, with MIC₅₀ and MIC₉₀ values of 2 µg/mL and 4 µg/mL, respectively. In contrast, only 5 (12.5%) isolates were susceptible to CAZ/AVI, with both MIC₅₀ and MIC₉₀ exceeding 16 µg/ml, indicating widespread resistance. The difference in susceptibility between the two antibiotics was statistically significant (p < 0.01). CONCLUSIONS: Colistin…
How strong is the evidence?
Evidence Hub reads this as a cross-sectional, done in people. Its evidence level is 4 of 5 (Low · observational). Observational designs can show an association but not prove cause. Reported size: 120 participants or records.
Read the paper
Related studies
- Pharmacokinetic aspects of retinal drug delivery
- A standardised method for interpreting the association between mutations and phenotypic drug resistance in Mycobacterium tuberculosis
- From Therapeutic Drug Monitoring to Model‐Informed Precision Dosing for Antibiotics
- Capsaicin, a novel inhibitor of the NorA efflux pump, reduces the intracellular invasion of Staphylococcus aureus
- In Vitro Pharmacodynamic Evaluation of the Mutant Selection Window Hypothesis Using Four Fluoroquinolones against Staphylococcus aureus
- Discovery of Potent, Selective Multidrug and Toxin Extrusion Transporter 1 (MATE1, SLC47A1) Inhibitors Through Prescription Drug Profiling and Computational Modeling
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.